Journal of Clinical Endocrinology & Metabolism, Vol 75, 110-115, Copyright © 1992 by Endocrine Society

ARTICLES

Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia

WH Daughaday and B Trivedi
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

We describe a modified RIA using a rabbit polyclonal antiserum directed against the first 21 amino acids of the E-domain (E-21) of proinsulin- like growth factor-II (pro-IGF-II). For standardization, we purified big IGF-II from patients with nonislet cell tumor hypoglycemia (NICTH). Under the conditions of our assay there was no significant interference from IGF-binding proteins. The big IGF-II present in the serum of a patient with NICTH displaced [125I]E-(1-21) from antibody parallel to our big IGF-II standard. We found a progressive rise in E-21 immunoactivity (IA) during childhood, with somewhat higher values in girls than in boys. In normal adults the mean E-21 IA level was 138 +/- 49 (+/- SD) micrograms/L. Women with twin pregnancies had higher E-21 IA than women with single pregnancies (302 +/- 66 compared with 120 +/- 18 micrograms/L). We found a marked elevation of E-21 IA in patients with NICTH due to sarcomas (n = 3), hepatoma (n = 2), adrenal carcinoma (n = 1), and carcinoma of the lung (n = 1). No elevation of E-21 IA was present in the serum of a hypoglycemic patient with a hypernephroma or another patient with carcinoma of the lung. Marked elevation of E-21 IA was observed in the serum of patients with renal failure receiving chronic hemodialysis. We conclude that this assay will prove useful in the diagnosis of NICTH in patients who are not azotemic and the investigation of the role of the kidney in clearing products of pro-IGF- II processing.

This article has been cited by other articles:

				J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993. [Abstract] [Full Text] [PDF]

				Q. Qiu, J.-Y. Jiang, M. Bell, B. K. Tsang, and A. Gruslin Activation of Endoproteolytic Processing of Insulin-Like Growth Factor-II in Fetal, Early Postnatal, and Pregnant Rats and Persistence of Circulating Levels in Postnatal Life Endocrinology, October 1, 2007; 148(10): 4803 - 4811. [Abstract] [Full Text] [PDF]

				U. Espelund, J. M. Bruun, B. Richelsen, A. Flyvbjerg, and J. Frystyk Pro- and mature IGF-II during diet-induced weight loss in obese subjects Eur. J. Endocrinol., December 1, 2005; 153(6): 861 - 869. [Abstract] [Full Text] [PDF]

				F. Miraki-Moud, A. B. Grossman, M. Besser, J. P. Monson, and C. Camacho-Hubner A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3819 - 3823. [Abstract] [Full Text] [PDF]

				J. van Doorn, C. M. Hoogerbrugge, J. G. Koster, R. J. Bloemen, K. Hoekman, A. H. Mudde, and S. C. van Buul-Offers Antibodies Directed against the E Region of Pro-Insulin-like Growth Factor-II Used to Evaluate Non-Islet Cell Tumor-induced Hypoglycemia Clin. Chem., October 1, 2002; 48(10): 1739 - 1750. [Abstract] [Full Text] [PDF]

				D. LeRoith Insulin-like Growth Factors in Pediatric Health and Disease J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4355 - 4361. [Full Text]

				D. Le Roith Tumor-Induced Hypoglycemia N. Engl. J. Med., September 2, 1999; 341(10): 757 - 758. [Full Text]

				Z.-D. Xu, L. Oey, S. Mohan, M. H. Kawachi, N.-S. Lee, J. J. Rossi, and Y. Fujita-Yamaguchi Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid in Vitro and in Prostate Cancer Cells Endocrinology, May 1, 1999; 140(5): 2134 - 2144. [Abstract] [Full Text]